Prostate Cancer Trial, Recruiting NCT06864533 Sponsor: Peking University First Hospital Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06864533
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with prostate cancer confirmed by a biopsy or surgery, with a high-grade cancer score (Gleason score of 9–10, or containing the most aggressive grade components)
  • People whose scans show no signs that the cancer has spread to distant parts of the body
  • People who are expected to receive standard intensive prostate treatment or radiation therapy after surgery
  • People whose doctors estimate they are likely to live longer than 12 months
  • People aged 18 or older
  • People who are largely able to carry out normal daily activities, as measured by a standard health performance scale (confirm with trial site)
  • People whose blood test results show healthy enough levels of white blood cells, infection-fighting cells (neutrophils), and platelets (confirm with trial site for exact values)

Who may not be able to join:

  • People who have had another type of cancer in the past, unless it was fully treated and resolved more than 5 years ago
  • People who have previously had radiation therapy to the abdomen area
  • People who have lost more than 10% of their body weight in the past 6 months
  • People who have an existing or ongoing condition that causes problems with bleeding
  • People who currently have an active infection
  • People who have significant heart or blood vessel problems — such as unstable chest pain, moderate-to-severe heart failure, certain irregular heart rhythms, or significant circulation problems in the limbs — or any condition that a cancer doctor considers unsafe for chemotherapy

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Peking University First Hospital
Registry
ClinicalTrials.gov
Start date
1 September 2019
Est. completion
1 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Failure-Free Survivall,FFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov